TABLE 2.

Statistical analysis of pharmacokinetic parameters after administration of ABT-773 alone and after coadministration with ranitidine or sucralfatea

VariableTest treatmentReference treatmentPoint estimate (%)90% confidence interval limit
Lower limitUpper limit
ABT-773M-1ABT-773M-1ABT-773M-1
CmaxbBA74.372.661.059.390.5d88.9
CA97.1101.279.782.6118.4123.9
AUC0-lastbBA82.876.768.361.8100.495.3
CA101.8101.184.081.4123.5125.6
AUC0-∞bBA84.278.369.863.9101.795.9
CA102.0100.984.582.3123.2123.5
t1/2bBA109.895.3100.483.4120.0108.9
CA101.7106.293.092.9111.2121.3
TmaxcBA114.0104.792.484.9135.5124.4
CA107.0107.085.487.2128.5126.7
MRTcBA111.698.1104.788.9118.4107.3
CA101.7101.694.892.3108.5110.8
  • a Treatment A, ABT-773 alone; treatment B, ABT-773 with ranitidine; treatment C, ABT-773 with sucralfate.

  • b Analysis was based on ln-transformed data and parametric testing.

  • c Analysis was based on untransformed data and parametric testing.

  • d P < 0.05.